Barclays PLC Has $1.24 Million Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Barclays PLC increased its stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 141.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 114,848 shares of the company’s stock after acquiring an additional 67,202 shares during the quarter. Barclays PLC’s holdings in 4D Molecular Therapeutics were worth $1,241,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp raised its stake in 4D Molecular Therapeutics by 1.8% during the third quarter. State Street Corp now owns 2,116,508 shares of the company’s stock worth $22,879,000 after buying an additional 37,232 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in 4D Molecular Therapeutics by 238.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock valued at $16,684,000 after acquiring an additional 1,087,147 shares during the last quarter. Novo Holdings A S grew its holdings in 4D Molecular Therapeutics by 7.1% during the 3rd quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock worth $16,215,000 after acquiring an additional 100,000 shares during the period. Redmile Group LLC lifted its stake in shares of 4D Molecular Therapeutics by 17.6% in the 3rd quarter. Redmile Group LLC now owns 1,262,090 shares of the company’s stock valued at $13,643,000 after purchasing an additional 188,655 shares during the period. Finally, Braidwell LP boosted its position in shares of 4D Molecular Therapeutics by 231.7% during the 3rd quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after purchasing an additional 855,990 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, September 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Morgan Stanley initiated coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They set an “underweight” rating and a $8.00 price target for the company. Finally, Chardan Capital restated a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.56.

4D Molecular Therapeutics Trading Down 4.5 %

Shares of NASDAQ:FDMT opened at $5.55 on Monday. The stock’s fifty day simple moving average is $7.50 and its two-hundred day simple moving average is $13.20. The stock has a market cap of $256.57 million, a PE ratio of -1.95 and a beta of 2.74. 4D Molecular Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $36.25.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.